Surface Oncology Shares Rise on Merck Collaboration
21 May 2020 - 1:10AM
Dow Jones News
By Colin Kellaher
Shares of Surface Oncology Inc. rose nearly 25% on Wednesday
after the immuno-oncology company announced a collaboration with
Merck & Co.
Surface said it will study its SRF617 investigational antibody
therapy in combination with Merck's Keytruda cancer drug in
patients with solid tumors.
The company separately said it sold about 10.9 million common
shares at $2.66 apiece, raising gross proceeds of $28.9 million and
exhausting the balance on its $30 million at-the-market
facility.
Surface shares were recently up 24.8% to $3.32.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 20, 2020 10:55 ET (14:55 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024